2024 is a significant year for addressing the urgency of Antimicrobial Resistance (AMR), which requires a broad, multi-stakeholder approach. Alarming statistics underpin the need for prompt action. In 2019, AMR was responsible for 1.27 million deaths and contributed to nearly five million overall. It’s a crisis that impacts every aspect of modern medicine, from surgery to cancer care.
The challenge is related not only to strengthening innovation but also to ensuring sustainable and appropriate access to both existing and new antibiotics, which requires a concerted approach to addressing the many interconnected challenges.
This session will delve into perspectives on the critical need for developing new antibiotics to treat resistant infections, and explore the path forward for concrete solutions to improve the innovation outlook and patient access. It will also explore how to maintain this priority high on the upcoming G7/G20 agendas.
Hosts:
CARB-X
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Chairs:
Deepali Patel
AMR Action Fund | Director of International Policy | United States of America
Speakers:
Khumbize Kandodo Chiponda
Minister of Health | Malawi
Joël Denis
Public Health Agency of Canada (PHAC) | Centre for Vaccine and Therapeutic Readiness | Director General | Canada
Dr. David Reddy
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland
Dr. Stefan Hagel
Jena University Hospital | Assistant Medical Director | Germany
Dr. Tamas Andras Koncz
Pfizer | Accord Chief Medical Officer (CMO) | Germany
Laurent Muschel
European Commission | Health Emergency Preparedness and Response (HERA) | Acting Director-General
Prof. Dr. Kevin Outterson
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) | Executive Director | United States of America
Florence Séjourné
AUROBAC THERAPEUTICS | CEO | France
Nour Shamas
World Health Organization (WHO) | AMR Survivors Taskforce Member & Antimicrobial Stewardship Consultant
2024 is a significant year for addressing the urgency of Antimicrobial Resistance (AMR), which requires a broad, multi-stakeholder approach. Alarming statistics underpin the need for prompt action. In 2019, AMR was responsible for 1.27 million deaths and contributed to nearly five million overall. It’s a crisis that impacts every aspect of modern medicine, from surgery to cancer care.
The challenge is related not only to strengthening innovation but also to ensuring sustainable and appropriate access to both existing and new antibiotics, which requires a concerted approach to addressing the many interconnected challenges.
This session will delve into perspectives on the critical need for developing new antibiotics to treat resistant infections, and explore the path forward for concrete solutions to improve the innovation outlook and patient access. It will also explore how to maintain this priority high on the upcoming G7/G20 agendas.
Hosts:
CARB-X
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Chairs:
Deepali Patel
AMR Action Fund | Director of International Policy | United States of America
Speakers:
Khumbize Kandodo Chiponda
Minister of Health | Malawi
Joël Denis
Public Health Agency of Canada (PHAC) | Centre for Vaccine and Therapeutic Readiness | Director General | Canada
Dr. David Reddy
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland
Dr. Stefan Hagel
Jena University Hospital | Assistant Medical Director | Germany
Dr. Tamas Andras Koncz
Pfizer | Accord Chief Medical Officer (CMO) | Germany
Laurent Muschel
European Commission | Health Emergency Preparedness and Response (HERA) | Acting Director-General
Prof. Dr. Kevin Outterson
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) | Executive Director | United States of America
Florence Séjourné
AUROBAC THERAPEUTICS | CEO | France
Nour Shamas
World Health Organization (WHO) | AMR Survivors Taskforce Member & Antimicrobial Stewardship Consultant
DE 
EN 
